Click to copy
Press release content from BusinessWire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from BusinessWire
Press release content from BusinessWire. The AP news staff was not involved in its creation.

Heart Transplant Rejection: Pipeline Review (H1 2018) Featuring Astellas Pharma, Heat Biologics, Noxxon Pharma, and TxCell - ResearchAndMarkets.com

October 19, 2018

DUBLIN--(BUSINESS WIRE)--Oct 19, 2018--The “Heart Transplant Rejection - Pipeline Review, H1 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This latest Pharmaceutical and Healthcare disease pipeline guide provides an overview of the Heart Transplant Rejection (Immunology) pipeline landscape.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Heart Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


Companies Featured

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/c7qdk6/heart_transplant?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181019005209/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs,Immunosuppressive Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 10/19/2018 06:06 AM/DISC: 10/19/2018 06:06 AM


All contents © copyright 2019 The Associated Press. All rights reserved.